Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epibrassinolide is a plant-derived steroid hormone belonging to the brassinosteroid family, characterized by a polyhydroxysteroid structure similar to vertebrate steroid hormones. Primarily recognized for its role in plant growth regulation, it has gained attention in oncology for its potential anti-cancer activities. Research indicates that epibrassinolide can inhibit cell proliferation and induce apoptosis in various cancer types, including colon cancer and small-cell lung cancer (SCLC), while exhibiting minimal toxicity toward non-cancerous cells. Its mechanism of action involves the induction of autophagy and cell cycle arrest, as well as the downregulation of the Wnt/β-catenin signaling pathway. In preclinical models, such as SCID mouse xenografts, epibrassinolide has demonstrated the ability to reduce tumor volume and diameter in a dose-dependent manner, potentially acting as a cytostatic agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epibrassinolide.